Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Steveminon Mar 31, 2021 9:51am
203 Views
Post# 32913139

Willow NR today - bad for Inmed

Willow NR today - bad for InmedDid you see the Willow news release today? There are so many good things in it for them which spells bad news for Inmed. I'm not even going to comment on most of it, but I do want to highlight one statement from the release:

"On the capital markets side, we have completed three successful financings bringing in supportive and sophisticated shareholders who have provided us with a healthy balance sheet to execute on our business plan."

Is that what Inmed has done? Does Adams do cap raises to bring in "sophisticated shareholders" or does he do them for desperate grabs of cash because he knows he's burning cash and producing nothing in return?

Adams holds much disdain for his shareholders and wants them to give him money, sit down and shut up. remember back in early 2018 when Adams did a private placement then 2 days later sold 95% of his shares? THAT'S HOW LITTLE ADAMS THINKS OF HIS SHAREHOLDERS. He basically said "I'm gonna dilute this company with another cap raise, then I'm gonna blow out all my shares and laugh in their faces."

That's the quality of guy you're dealing with.
<< Previous
Bullboard Posts
Next >>